Where do we stand with hepatoblastoma?

Schnater, J. Marco; Köhler, S. Eleonore; Lamers, Wouter H.; Schweinitz, Dietrich von; Aronson, Daniël C.

doi:10.1002/cncr.11585

Cited by 164 publications

(146 citation statements)

References 95 publications

(108 reference statements)

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…It affects approximatively 1:1,000,000 children under the age of 15 and most predominantly between 6 months and 3 years (1,2). It has been reported that the risk of developing hepatoblastoma is increased in subjects that are afflicted by several syndromes, such as Beckwith-Wiedemann syndrome (BWS) (3), hemihypertrophy or familial adenomatosis polyposis (FAP) (4).…”

Section: Abstract Hepatoblastoma Is the Most Common Pediatric Liver mentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Innovations for Targeting Hepatoblastoma

Garnier

Ilmer

Kappler

et al. 2016

View full text Add to dashboard Cite

Section: Abstract Hepatoblastoma Is the Most Common Pediatric Liver mentioning

confidence: 99%

“…One of the major breakthroughs is the use of platinum-based chemotherapeutic agents (such as cisplatin and carboplatin), which greatly improved the survival in children from 30% to 70% (2).…”

Section: Conventional Treatment Strategiesmentioning

confidence: 99%

Therapeutic Innovations for Targeting Hepatoblastoma

Garnier

Ilmer

Kappler

et al. 2016

View full text Add to dashboard Cite

“…Different from HCC, it is an embryonal tumor derived from undifferentiated embryonal tissue. Although its etiology remains unclear, it usually occurs in childhood with an annual incidence of 0.5-1.5 diagnoses per 1 million children younger than 15 yr of age in Western countries (3). The incidence rate of HB is higher in patients with the Beckwith-Wiedemann syndrome or familial adenomatous polyposis (4,5).…”

Section: Introductionmentioning

confidence: 99%

Comparison of protein expression patterns between hepatocellular carcinoma cell lines and a hepatoblastoma cell line

et al. 2004

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) and hepatoblastoma (HB) are malignancies of the liver with different etiologies, but the HB cell line HepG2 has been frequently used in various studies of HCC. In this study, we compare the protein expression patterns between HepG2 cells and three HCC cell lines, HKCI-2, HKCI-3, and HKCI-4, respectively. The cell lysates of individual cell lines were separated by twodimensional polyacrylamide gel electrophoresis. The protein spots in the gel images were quantified and compared by image analysis software. The differentially expressing proteins were then identified by tryptic peptide mass fingerprinting. Compared with the HepG2 cells, the normalized quantities of 49 and 58 protein spots were found to be at least twofold higher and twofold lower, respectively, in all three HCC cell lines. The differentially expressed proteins can be grouped into structural proteins (annexins, transgelin, laminin receptor), stress-induced proteins (HSP27, 60, and 70), enzymes (aldehyde dehydrogenase, pyruvate kinase, ␣-enolase, etc.), and transcription factors (far upstream element binding protein 2, GTP-binding nuclear protein RAN).

show abstract

“…

…”

mentioning

confidence: 99%

Hepatoblastoma Etiopathogenesis

RIR¹,

Armengol²,

JJG³

2016

J Carcinog Mutagene

View full text Add to dashboard Cite

EditorialHepatoblastoma (HB) is the predominant form of pediatric liver cancer, usually arising in young children under 3 years of age [1], but it is a rare pediatric cancer with a very low worldwide incidence (<2 cases per million children under 18 years) [2]. Hepatocellular carcinoma (HCC) can also be diagnosed in children but with much lower incidence, usually found in the teenage population in association with predisposing conditions, such as the presence of underlying liver diseases (i.e., tyrosinemia and several cholestatic syndromes). As compared with HB, the prognostic of HCC is often poorer. A third type of primary liver cancer that appears at the late childhood and adolescence was initially called transitional liver cell tumor (TLCT), because it has a mixture of histological patterns characteristic of HB and HCC [3]. This cancer has been recently classified in a new provisional category named hepatocellular neoplasm not otherwise specified [4], awaiting for a better characterization, in an international symposium aiming to develop a consensus classification system for pediatric liver malignancies.Overall survival of patients with HB has notably improved from 30% in the 1970s to 70-80% nowadays thanks to the incorporation to the treatment of adjuvant and neoadjuvant chemotherapy using cisplatin and doxorubicin combined with efficient surgical approaches, including liver transplantation [5]. However, there are very limited treatment options for patients suffering from immature, invasive, and metastatic HB resistant to conventional first-line chemotherapeutic protocols, being the survival of these patients usually less than 3 years. The International Childhood Liver Tumor Strategy Group (SIOPEL) defined a prognostic stratification system of HB patients taking into consideration PRETEXT stage, metastatic disease, serum α-fetoprotein levels, multifocality, age and histology characterized by small undifferentiated cells [6]. Importantly, a recent study of the Children's Hepatic tumors International Collaboration (CHIC) group has confirmed these prognostic risk factors and identified new ones through a large-scale analysis using an extensive database including 1605 HB cases [7]. Patient stratification and treatment taking into account molecular biomarkers are the future challenges facing clinicians. High-throughput molecular studies of aggressive tumors highly refractory to anticancer drugs have the unique potential to provide a rational basis and new tools (biomarkers/molecular targets) for improving patient stratification and defining more specific and molecular-based therapies.Because HB is a rare tumor, most of the few existing studies have been carried out in small groups of patients, and this fact, together with the existence of several histologic subtypes without a clear consensus for their classification, has hindered advances in the characterization of different aspects of this liver cancer. Histologically, HB is usually composed of combinations of epithelial, mesenchymal, undifferentiated and other ...

show abstract

Where do we stand with hepatoblastoma?

Cited by 164 publications

References 95 publications

Therapeutic Innovations for Targeting Hepatoblastoma

Therapeutic Innovations for Targeting Hepatoblastoma

Comparison of protein expression patterns between hepatocellular carcinoma cell lines and a hepatoblastoma cell line

Hepatoblastoma Etiopathogenesis

Contact Info

Product

Resources

About